| Thyroid carcinoma
Tirosint SOL vs Retevmo
Side-by-side clinical, coverage, and cost comparison for thyroid carcinoma.Deep comparison between: Tirosint vs Retevmo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRetevmo has a higher rate of injection site reactions vs Tirosint based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Retevmo but not Tirosint, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tirosint
Retevmo
At A Glance
Oral
Daily
Thyroid hormone (synthetic T4)
Oral
Twice daily
RET kinase inhibitor
Indications
- Hypothyroidism
- Thyroid carcinoma
- Non-Small Cell Lung Carcinoma
- Medullary carcinoma of thyroid
- Thyroid carcinoma
Dosing
Hypothyroidism Once daily oral dose on empty stomach, 15 minutes before breakfast; adults start at 1.6 mcg/kg/day (lower in cardiac or geriatric patients), titrate by 12.5-25 mcg every 4-6 weeks; pediatric dosing weight-based by age (1.6-15 mcg/kg/day), titrated every 2 weeks; pregnant patients may require increased dose monitored every 4 weeks.
Thyroid carcinoma Once daily oral dose; dosage based on target level of TSH suppression for the stage and clinical status of well-differentiated thyroid cancer.
Non-Small Cell Lung Carcinoma, Medullary carcinoma of thyroid, Thyroid carcinoma Adults and adolescents >= 12 years: 120 mg orally twice daily (< 50 kg) or 160 mg orally twice daily (>= 50 kg); pediatric patients 2 to < 12 years: 40 mg three times daily to 160 mg twice daily orally based on body surface area; administered until disease progression or unacceptable toxicity.
Contraindications
- Hypersensitivity to glycerol (inactive ingredient in TIROSINT-SOL)
- Uncorrected adrenal insufficiency
—
Adverse Reactions
Most common Fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating, headache, hyperactivity, nervousness, anxiety, irritability, insomnia, tremors, muscle weakness, palpitations, tachycardia, diarrhea, vomiting, abdominal cramps, hair loss, flushing, rash, decreased bone mineral density, menstrual irregularities, impaired fertility
Serious Arrhythmias, increased blood pressure, heart failure, angina, myocardial infarction, cardiac arrest, seizures (rare); pseudotumor cerebri and slipped capital femoral epiphysis in pediatric patients
Hypersensitivity Urticaria, pruritus, skin rash, flushing, angioedema, abdominal pain, nausea, vomiting, diarrhea, fever, arthralgia, serum sickness, wheezing
Most common (>=25%) edema, diarrhea, fatigue, dry mouth, hypertension, abdominal pain, constipation, rash, nausea, headache
Serious hepatotoxicity, interstitial lung disease/pneumonitis, hypertension, QT interval prolongation, hemorrhagic events, hypersensitivity, tumor lysis syndrome, impaired wound healing, hypothyroidism, slipped capital femoral epiphysis in adolescents
Postmarketing Stevens-Johnson Syndrome
Pharmacology
Synthetic T4 hormone (levothyroxine sodium) that exerts physiologic effects through control of DNA transcription and protein synthesis by binding thyroid receptor proteins attached to DNA in cell nuclei; the predominant active form T3 is derived approximately 80% from peripheral deiodination of T4, and oral levothyroxine maintains normal T4 levels when endogenous production is deficient.
Selpercatinib is a kinase inhibitor that selectively inhibits wild-type RET and multiple mutated RET isoforms (including gene fusions and activating point mutations) as well as VEGFR1 and VEGFR3, and at clinically achievable concentrations also inhibits FGFR1, 2, and 3, blocking constitutive RET signaling that acts as an oncogenic driver promoting tumor cell proliferation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tirosint
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
No coverage data available for Retevmo.
UnitedHealthcare
Tirosint
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (0/8)
Retevmo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Tirosint
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Retevmo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Tirosint.
No savings programs available for Retevmo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TirosintView full Tirosint profile
RetevmoView full Retevmo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.